Anti-platelet therapy in diabetic and non-diabetic progressive renal failure.
Gordge
M P
MP
Rylance
P B
PB
Neild
G H
GH
D001241:Aspirin / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000493:pharmacokinetics; D003928:Diabetic Nephropathies / Q000188:drug therapy*; D004176:Dipyridamole / Q000627:therapeutic use*; D004281:Docosahexaenoic Acids; D004338:Drug Combinations; D015118:Eicosapentaenoic Acid; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use*; D005260:Female; D005395:Fish Oils / Q000627:therapeutic use*; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006487:Hemostasis / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000188:drug therapy; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D008297:Male; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011507:Proteinuria / Q000188:drug therapy
D004338:Drug Combinations; D015525:Fatty Acids, Omega-3; D005395:Fish Oils; C045153:Maxepa; D010975:Platelet Aggregation Inhibitors; D004281:Docosahexaenoic Acids; D004176:Dipyridamole; D015118:Eicosapentaenoic Acid; D003404:Creatinine; D001241:Aspirin